<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Glycogen debrancher deficiency (glycogen storage disease III, Cori disease)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Glycogen debrancher deficiency (glycogen storage disease III, Cori disease)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Glycogen debrancher deficiency (glycogen storage disease III, Cori disease)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William J Craigen, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Basil T Darras, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sihoun Hahn, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth TePas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 07, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Glycogen is the stored form of glucose and serves as a buffer for glucose needs. It is composed of long polymers of a 1-4 linked glucose, interrupted by a 1-6 linked branch point every 4 to 10 residues. Glycogen is formed in periods of dietary carbohydrate loading and broken down when glucose demand is high or dietary availability is low  (<a class="graphic graphic_figure graphicRef81164" href="/d/graphic/81164.html" rel="external">figure 1</a>).</p><p>There are a number of inborn errors of glycogen metabolism that result from mutations in genes for virtually all of the proteins involved in glycogen synthesis, degradation, or regulation. Those disorders that result in abnormal storage of glycogen are known as glycogen storage diseases (GSDs). They have largely been categorized by number according to the chronology of recognition of the responsible enzyme defect  (<a class="graphic graphic_table graphicRef54417" href="/d/graphic/54417.html" rel="external">table 1</a>). The age of onset varies from in utero to adulthood.</p><p>Glycogen is most abundant in liver and muscle, which are most affected by these disorders. The physiologic importance of a given enzyme in liver and muscle determines the clinical manifestations of the disease.</p><p class="bulletIndent1"><span class="glyph">●</span>The main role of glycogen in the liver is to store glucose for release to tissues that are unable to synthesize significant amounts during fasting. The major manifestations of disorders of glycogen metabolism affecting the liver are hypoglycemia and hepatomegaly. (See  <a class="medical medical_review" href="/d/html/1808.html" rel="external">"Physiologic response to hypoglycemia in healthy individuals and patients with diabetes mellitus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Glycogen serves as the primary source of energy for high-intensity muscle activity by providing substrates for the generation of adenosine triphosphate (ATP). The major manifestations of disorders of glycogen metabolism affecting muscle are muscle cramps, exercise intolerance and easy fatigability, and progressive weakness.</p><p></p><p>This topic will review glycogen debrancher deficiency (GSD III). An overview of GSD is presented separately. (See  <a class="medical medical_review" href="/d/html/2941.html" rel="external">"Overview of inherited disorders of glucose and glycogen metabolism"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Glycogen debrancher deficiency (GSD III, MIM #232400) is also known as Cori disease, Forbes disease, and limit dextrinosis [<a href="#rid1">1</a>].</p><p>Glycogenolysis proceeds with stepwise removal of glucose molecules through the action of the enzyme phosphorylase  (<a class="graphic graphic_figure graphicRef81164" href="/d/graphic/81164.html" rel="external">figure 1</a>). Depolymerization of glycogen by phosphorylase halts when glycogen branches have been reduced to two to four linked glucose molecules (limit dextrins). Glycogen debrancher enzyme has two catalytic activities. One is the cleavage of a dextrin branch from the remaining glycogen molecule (amylo-1,6-glucosidase activity). The other is the transfer of the dextrin to the free end of a dextran polymer (oligo-1,4-1,4-glucanotransferase activity). The transferred dextrin may then be further depolymerized by phosphorylase. The clinical features and enzyme activities in affected patients are quite variable.</p><p class="headingAnchor" id="H3"><span class="h1">GENETICS</span><span class="headingEndMark"> — </span>GSD III is inherited as an autosomal-recessive trait. It is caused by mutations in the gene that encodes the debrancher enzyme (amyloglucosidase [<em>AGL</em>] gene), which is located at 1p21 [<a href="#rid2">2,3</a>]. Differential ribonucleic acid (RNA) transcription results in the generation of muscle and liver isoforms, with different tissue-specific promoters and an alternative usage of the first exon. At least six transcript isoforms are produced by alternative splicing, with differing tissue distributions [<a href="#rid4">4</a>].</p><p>A variety of pathogenic variants are recognized [<a href="#rid5">5</a>]. These allow deoxyribonucleic acid (DNA) diagnosis, particularly in populations with founder mutations. The highest prevalence of GSD III (estimated at 1 in 2500) is in the Canadian Inuit population and is due to a homozygous frameshift deletion, c.4456delT [<a href="#rid6">6</a>]. GSD III in the Faroe Islands is due to the R408X truncating variant [<a href="#rid7">7</a>]. Sephardic Jewish patients in Israel have the 4455delT variant, with a disease frequency of 1 in 5400 [<a href="#rid8">8</a>]. A novel missense pathogenic variant (p.R1147G) leading to isolated glucosidase deficiency, along with nine other <em>AGL</em> pathogenic variants, have been described in 23 patients of Turkish ancestry [<a href="#rid9">9</a>].</p><p>Patients with both myopathy and liver involvement have an enzyme defect in both tissues. In those with only liver involvement, enzyme activity is absent in liver and normal in muscle.</p><p class="headingAnchor" id="H4"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>Clinical manifestations of the disease are variable and are classified as four types. The majority of patients have both liver and muscle involvement (GSD IIIa). Liver involvement without muscle disease occurs in approximately 15 percent of patients (GSD IIIb). In the rare types IIIc and IIId, activity of amylo-1,6-glucosidase or oligo-1,4-1,4-glucanotransferase is selectively absent. Clinical features depend upon the tissue involved.</p><p>GSD III presents during infancy and childhood with hepatomegaly and hypoglycemia due to liver disease. Affected patients also have ketoacidosis, hyperlipidemia, and growth retardation, features that may be indistinguishable from GSD I [<a href="#rid10">10</a>]. However, GSD IIIa can be distinguished from GSD I by hypotonia, weakness, wasting of skeletal muscle, and involvement of the heart. In one series of 21 patients alive at the time of the study and with an average age of nearly 20 years, signs and symptoms of the disease had ameliorated after childhood, but approximately 20 percent had significant complications [<a href="#rid11">11</a>]. Osteopenia and osteoporosis is a common feature and appears related to metabolic control [<a href="#rid12">12</a>].</p><p>Hepatomegaly and transaminases typically improve with age and treatment, normalizing after puberty in the majority of cases. Adenomas are occasionally seen [<a href="#rid13">13</a>] and can progress to hepatocellular carcinoma [<a href="#rid14">14</a>]. Rare patients progress to cirrhotic liver disease [<a href="#rid15">15</a>]. The overall rate of severe liver disease in an international cohort of 175 adult and pediatric patients was 11 percent [<a href="#rid16">16</a>]. Persistent hypercholesterolemia was observed in a third of adult and pediatric cases, with hypertriglyceridemia almost universal in children and persistently elevated in 40 percent of adults.</p><p>Muscle weakness, which is less prominent in children with GSD IIIa, is the predominant feature in adults. In the latter group, progressive weakness and distal muscle wasting are typical and, in some cases, are associated with peripheral neuropathy [<a href="#rid17">17-21</a>]. Muscle pain with minimal exercise was reported in a third of patients with GSD IIIa and, along with distal myopathy, was associated with the development of cardiomyopathy [<a href="#rid16">16</a>]. Affected females may have polycystic ovaries but remain fertile, and guidelines for management during pregnancies have been proposed [<a href="#rid22">22</a>]. There are also reports of neurocognitive impairment in adults, with limitations in executive functions and social cognition [<a href="#rid23">23</a>].</p><p>Overall, 58 percent of the 151 patients with GSD IIIa in an international cohort had cardiac complications, with 15 percent exhibiting cardiomyopathy [<a href="#rid16">16</a>]. Cardiomyopathy with left ventricular hypertrophy is a frequent complication during childhood in patients with GSD IIIa, and it is associated with potential risk of serious arrhythmia and symptomatic heart failure [<a href="#rid24">24</a>]. Cardiomyopathy in conjunction with hepatomegaly and hypoglycemia has been described in adult patients with GSD IIIa [<a href="#rid25">25,26</a>]. A novel homozygous pathogenic variant, R285X, was detected in a 42-year-old Japanese man with hypertrophic cardiomyopathy. This nonsense mutation resulted in truncation of the AGL protein [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H5"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Serum creatine kinase concentration is elevated in patients with muscle involvement. Electromyography reveals myopathic changes. Myopathic findings and neuropathy are more likely to be detected by electromyography and nerve conduction studies in older patients, even in those with GSD IIIb [<a href="#rid28">28</a>]. Ischemic forearm muscle testing results in a smaller-than-expected increase in serum lactate concentration. (See  <a class="medical medical_review" href="/d/html/6193.html" rel="external">"Approach to the metabolic myopathies", section on 'Semi-ischemic exercise test'</a>.)</p><p>Patients with liver disease have elevated serum transaminase levels. In contrast to GSD I, consistent hypertriglyceridemia, lactic acidosis, and hyperuricemia are not present in GSD III.</p><p>DNA testing of the <em>AGL</em> gene is commercially available. The diagnosis can be confirmed by measuring reduced or absent debrancher enzyme activity in liver, muscle, or fibroblasts [<a href="#rid29">29</a>]. Liver histology reveals glycogen storage. Fibrosis may be prominent, although fat infiltration usually is not seen. Muscle histology is characterized by free glycogen accumulation. The glycogen particles are periodic acid-Schiff (PAS) stain positive, digestible by diastase, and appear as normal particles by electron microscopy.</p><p class="headingAnchor" id="H6"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>There is no specific therapy for GSD III. Symptomatic treatment includes avoidance of hypoglycemia. This tends to be less severe than in GSD I, so treatment is less demanding. Frequent feeding of uncooked cornstarch (approximately 0.5 to 1 g/kg/dose, four to five times a day) and continuous feeding of formula at night are used to maintain glucose levels [<a href="#rid29">29</a>]. Because GSD III patients have intact gluconeogenesis, a high-protein diet (3 g/kg/day) is useful [<a href="#rid30">30</a>]. Unlike GSD I, avoiding fructose and galactose in the diet is not necessary. A high-protein diet (30 percent of total energy) and avoidance of overtreatment with cornstarch can reverse and may prevent GSD type IIIa-related cardiomyopathy [<a href="#rid31">31</a>]. A high-fat diet may also improve cardiomyopathy, as was seen in two siblings seven and five years of age affected with GSD IIIa 12 months after starting a high-fat (60 percent), high-protein (25 percent), and low-carbohydrate (15 percent) diet [<a href="#rid32">32</a>].</p><p>In a pilot study, the use of physically modified cornstarch (waxy maize heat-modified 20 [WMHM20]), a form of starch containing higher amounts of branched polymers, provided better short-term metabolic control and longer duration of euglycemia than uncooked cornstarch in patients with GSD Ia, Ib, and III [<a href="#rid33">33,34</a>]. Modified cornstarch also appears effective in young children [<a href="#rid35">35</a>].</p><p>A high-protein diet appears successful in reversing heart failure in some patients [<a href="#rid31">31,36</a>], and a high-fat diet improves cardiomyopathy [<a href="#rid32">32,37</a>]. As an example, a 34-year-old patient with GSD IIIa with associated hypertrophic cardiomyopathy was treated with a modified Atkins ketogenic diet (high fat, high protein with 20 grams carbohydrate per day, fat:protein, 1 to 2:1). Ejection fraction increased from 30 to 45 percent, liver enzymes were reduced, and creatine kinase plasma level decreased from 568 to 327 units/L after 12 months of treatment. In addition, physical activity increased and health-related quality of life improved over time [<a href="#rid37">37</a>]. A high-fat diet may be beneficial in children and adults with GSD IIIa and associated cardiomyopathy; however, careful long-term monitoring for potential complications is necessary to detect early growth delay, liver inflammation, and development of hepatocellular carcinoma [<a href="#rid38">38</a>].</p><p>Excellent graft and patient survival has been shown in a small number of patients with GSD III who underwent living donor or deceased donor liver transplantation [<a href="#rid39">39,40</a>].</p><p>In a small series, liver transplantation improved metabolic control but did not improve muscle disease [<a href="#rid40">40,41</a>]. Liver transplantation is an option in patients with severe liver dysfunction, hepatic cirrhosis, and/or hepatocellular carcinoma [<a href="#rid29">29</a>]. However, it may worsen myopathy and cardiomyopathy.</p><p>Recombinant human acid alpha-glucosidase (rhGAA, <a class="drug drug_general" data-topicid="9280" href="/d/drug information/9280.html" rel="external">alglucosidase alfa</a>), the enzyme defective in Pompe disease, significantly reduced glycogen levels in muscle cells from two patients with GSD IIIa in vitro, indicating that rhGAA is a potential novel therapy for GSD III. In vivo studies are needed to confirm clinical efficacy [<a href="#rid42">42</a>]. In another in vitro study, rapamycin inhibited glycogen accumulation in muscle cells from a patient with GSD IIIa [<a href="#rid43">43</a>]. In vivo studies in dogs with GSD IIIa showed that rapamycin reduced muscle glycogen content, suggesting that this is another potential therapy for GSD IIIa. (See  <a class="medical medical_review" href="/d/html/2905.html" rel="external">"Lysosomal acid alpha-glucosidase deficiency (Pompe disease, glycogen storage disease II, acid maltase deficiency)", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis and genetics</strong> – Glycogen debrancher enzyme plays an important role in glycogenolysis  (<a class="graphic graphic_figure graphicRef81164" href="/d/graphic/81164.html" rel="external">figure 1</a>). Glycogen debrancher deficiency (glycogen storage disease [GSD] III, Cori disease, Forbes disease, limit dextrinosis) is inherited as an autosomal-recessive trait. It is caused by mutations in the gene that encodes the debrancher enzyme (amyloglucosidase [<em>AGL</em>] gene). (See <a class="local">'Pathogenesis'</a> above and <a class="local">'Genetics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – The clinical manifestations vary depending upon the involved tissues (muscle and/or liver) and enzyme activities. In infants and children, GSD III presents with hepatomegaly and hypoglycemia due to liver disease. Additional features may include growth failure, hypotonia, weakness, wasting of skeletal muscle, involvement of the heart, ketoacidosis, osteoporosis, and hyperlipidemia. Muscle weakness is the prominent feature in adults. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – Laboratory studies that support the diagnosis of GSD III in patients with muscle involvement include elevated serum creatine kinase concentration in patients, myopathic changes on electromyography, and a smaller-than-expected increase in serum lactate concentration during ischemic forearm muscle testing. Laboratory studies that support the diagnosis in patients with liver involvement include elevated serum transaminase levels. DNA testing is commercially available. The diagnosis can be confirmed by measuring reduced or absent debrancher enzyme activity in liver, muscle, or fibroblasts. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – There is no specific therapy for GSD III. Symptomatic treatment includes avoidance of hypoglycemia (eg, frequent feeding of uncooked cornstarch, continuous formula feeding of infant overnight). A high-protein diet may be helpful, and a high-fat diet may be appropriate for those with cardiomyopathy. (See <a class="local">'Treatment'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Lucchiari S, Fogh I, Prelle A, et al. Clinical and genetic variability of glycogen storage disease type IIIa: seven novel AGL gene mutations in the Mediterranean area. Am J Med Genet 2002; 109:183.</a></li><li><a class="nounderline abstract_t">Yang-Feng TL, Zheng K, Yu J, et al. Assignment of the human glycogen debrancher gene to chromosome 1p21. Genomics 1992; 13:931.</a></li><li><a class="nounderline abstract_t">Yang BZ, Ding JH, Enghild JJ, et al. Molecular cloning and nucleotide sequence of cDNA encoding human muscle glycogen debranching enzyme. J Biol Chem 1992; 267:9294.</a></li><li><a class="nounderline abstract_t">Bao Y, Dawson TL Jr, Chen YT. Human glycogen debranching enzyme gene (AGL): complete structural organization and characterization of the 5' flanking region. Genomics 1996; 38:155.</a></li><li><a class="nounderline abstract_t">Lu C, Qiu Z, Sun M, et al. Spectrum of AGL mutations in Chinese patients with glycogen storage disease type III: identification of 31 novel mutations. J Hum Genet 2016; 61:641.</a></li><li><a class="nounderline abstract_t">Rousseau-Nepton I, Okubo M, Grabs R, et al. A founder AGL mutation causing glycogen storage disease type IIIa in Inuit identified through whole-exome sequencing: a case series. CMAJ 2015; 187:E68.</a></li><li><a class="nounderline abstract_t">Santer R, Kinner M, Steuerwald U, et al. Molecular genetic basis and prevalence of glycogen storage disease type IIIA in the Faroe Islands. Eur J Hum Genet 2001; 9:388.</a></li><li><a class="nounderline abstract_t">Parvari R, Moses S, Shen J, et al. A single-base deletion in the 3'-coding region of glycogen-debranching enzyme is prevalent in glycogen storage disease type IIIA in a population of North African Jewish patients. Eur J Hum Genet 1997; 5:266.</a></li><li><a class="nounderline abstract_t">Aoyama Y, Ozer I, Demirkol M, et al. Molecular features of 23 patients with glycogen storage disease type III in Turkey: a novel mutation p.R1147G associated with isolated glucosidase deficiency, along with 9 AGL mutations. J Hum Genet 2009; 54:681.</a></li><li><a class="nounderline abstract_t">Geberhiwot T, Alger S, McKiernan P, et al. Serum lipid and lipoprotein profile of patients with glycogen storage disease types I, III and IX. J Inherit Metab Dis 2007; 30:406.</a></li><li><a class="nounderline abstract_t">Hershkovitz E, Forschner I, Mandel H, et al. Glycogen storage disease type III in Israel: presentation and long-term outcome. Pediatr Endocrinol Rev 2014; 11:318.</a></li><li><a class="nounderline abstract_t">Melis D, Rossi A, Pivonello R, et al. Reduced bone mineral density in glycogen storage disease type III: evidence for a possible connection between metabolic imbalance and bone homeostasis. Bone 2016; 86:79.</a></li><li><a class="nounderline abstract_t">Labrune P, Trioche P, Duvaltier I, et al. Hepatocellular adenomas in glycogen storage disease type I and III: a series of 43 patients and review of the literature. J Pediatr Gastroenterol Nutr 1997; 24:276.</a></li><li><a class="nounderline abstract_t">Oterdoom LH, Verweij KE, Biermann K, et al. Hepatocellular Adenomas and Carcinoma in Asymptomatic, Non-Cirrhotic Type III Glycogen Storage Disease. J Gastrointestin Liver Dis 2015; 24:515.</a></li><li><a class="nounderline abstract_t">Markowitz AJ, Chen YT, Muenzer J, et al. A man with type III glycogenosis associated with cirrhosis and portal hypertension. Gastroenterology 1993; 105:1882.</a></li><li><a class="nounderline abstract_t">Sentner CP, Hoogeveen IJ, Weinstein DA, et al. Glycogen storage disease type III: diagnosis, genotype, management, clinical course and outcome. J Inherit Metab Dis 2016; 39:697.</a></li><li><a class="nounderline abstract_t">DiMauro S, Hartwig GB, Hays A, et al. Debrancher deficiency: neuromuscular disorder in 5 adults. Ann Neurol 1979; 5:422.</a></li><li><a class="nounderline abstract_t">Murase T, Ikeda H, Muro T, et al. Myopathy associated with type 3 glycogenosis. J Neurol Sci 1973; 20:287.</a></li><li><a class="nounderline abstract_t">Moses SW, Gadoth N, Bashan N, et al. Neuromuscular involvement in glycogen storage disease type III. Acta Paediatr Scand 1986; 75:289.</a></li><li><a class="nounderline abstract_t">Brunberg JA, McCormick WF, Schochet SS. Type 3 glycogenosis. An adult with diffuse weakness and muscle wasting. Arch Neurol 1971; 25:171.</a></li><li><a class="nounderline abstract_t">Ugawa Y, Inoue K, Takemura T, Iwamasa T. Accumulation of glycogen in sural nerve axons in adult-onset type III glycogenosis. Ann Neurol 1986; 19:294.</a></li><li><a class="nounderline abstract_t">Beneru D, Tchan MC, Billmore K, Nayyar R. Glycogen storage disease type IIIa in pregnant women: A guide to management. JIMD Rep 2022; 63:216.</a></li><li><a class="nounderline abstract_t">Michon CC, Gargiulo M, Hahn-Barma V, et al. Cognitive profile of patients with glycogen storage disease type III: a clinical description of seven cases. J Inherit Metab Dis 2015; 38:573.</a></li><li><a class="nounderline abstract_t">Austin SL, Proia AD, Spencer-Manzon MJ, et al. Cardiac Pathology in Glycogen Storage Disease Type III. JIMD Rep 2012; 6:65.</a></li><li><a class="nounderline abstract_t">Cuspidi C, Sampieri L, Pelizzoli S, et al. Obstructive hypertrophic cardiomyopathy in type III glycogen-storage disease. Acta Cardiol 1997; 52:117.</a></li><li><a class="nounderline abstract_t">Akazawa H, Kuroda T, Kim S, et al. Specific heart muscle disease associated with glycogen storage disease type III: clinical similarity to the dilated phase of hypertrophic cardiomyopathy. Eur Heart J 1997; 18:532.</a></li><li><a class="nounderline abstract_t">Ogimoto A, Okubo M, Okayama H, et al. A Japanese patient with cardiomyopathy caused by a novel mutation R285X in the AGL gene. Circ J 2007; 71:1653.</a></li><li><a class="nounderline abstract_t">Hobson-Webb LD, Austin SL, Bali DS, Kishnani PS. The electrodiagnostic characteristics of Glycogen Storage Disease Type III. Genet Med 2010; 12:440.</a></li><li class="breakAll">Schreuder AB, Rossi A, Grunert SC, Derks TGJ. Glycogen storage diseases type III. In: GeneReviews [Internet], Adam MP, Ardinger HH, Pagon RA, et al (Eds), University of Washington, 2022.</li><li><a class="nounderline abstract_t">Goldberg T, Slonim AE. Nutrition therapy for hepatic glycogen storage diseases. J Am Diet Assoc 1993; 93:1423.</a></li><li><a class="nounderline abstract_t">Dagli AI, Zori RT, McCune H, et al. Reversal of glycogen storage disease type IIIa-related cardiomyopathy with modification of diet. J Inherit Metab Dis 2009; 32 Suppl 1:S103.</a></li><li><a class="nounderline abstract_t">Brambilla A, Mannarino S, Pretese R, et al. Improvement of Cardiomyopathy After High-Fat Diet in Two Siblings with Glycogen Storage Disease Type III. JIMD Rep 2014; 17:91.</a></li><li><a class="nounderline abstract_t">Bhattacharya K, Orton RC, Qi X, et al. A novel starch for the treatment of glycogen storage diseases. J Inherit Metab Dis 2007; 30:350.</a></li><li><a class="nounderline abstract_t">Ross KM, Brown LM, Corrado MM, et al. Safety and Efficacy of Chronic Extended Release Cornstarch Therapy for Glycogen Storage Disease Type I. JIMD Rep 2016; 26:85.</a></li><li><a class="nounderline abstract_t">Hijazi G, Pai N, Nagy LL, et al. Use of waxy maize heat modified starch in the treatment of children between 2 and 5 years with glycogen storage disease type I: A retrospective study. Mol Genet Metab Rep 2019; 21:100536.</a></li><li><a class="nounderline abstract_t">Sentner CP, Caliskan K, Vletter WB, Smit GP. Heart Failure Due to Severe Hypertrophic Cardiomyopathy Reversed by Low Calorie, High Protein Dietary Adjustments in a Glycogen Storage Disease Type IIIa Patient. JIMD Rep 2012; 5:13.</a></li><li><a class="nounderline abstract_t">Francini-Pesenti F, Tresso S, Vitturi N. Modified Atkins ketogenic diet improves heart and skeletal muscle function in glycogen storage disease type III. Acta Myol 2019; 38:17.</a></li><li><a class="nounderline abstract_t">Rossi A, Hoogeveen IJ, Bastek VB, et al. Dietary lipids in glycogen storage disease type III: A systematic literature study, case studies, and future recommendations. J Inherit Metab Dis 2020; 43:770.</a></li><li><a class="nounderline abstract_t">Iyer SG, Chen CL, Wang CC, et al. Long-term results of living donor liver transplantation for glycogen storage disorders in children. Liver Transpl 2007; 13:848.</a></li><li><a class="nounderline abstract_t">Beyzaei Z, Shamsaeefar A, Kazemi K, et al. Liver transplantation in glycogen storage disease: a single-center experience. Orphanet J Rare Dis 2022; 17:127.</a></li><li><a class="nounderline abstract_t">Zobeiri M. Liver Transplantation in a Myopathic Patient with Glycogen Storage Disease Type IIIa and Decompensated Cirrhosis. Int J Organ Transplant Med 2017; 8:217.</a></li><li><a class="nounderline abstract_t">Sun B, Fredrickson K, Austin S, et al. Alglucosidase alfa enzyme replacement therapy as a therapeutic approach for glycogen storage disease type III. Mol Genet Metab 2013; 108:145.</a></li><li><a class="nounderline abstract_t">Yi H, Brooks ED, Thurberg BL, et al. Correction of glycogen storage disease type III with rapamycin in a canine model. J Mol Med (Berl) 2014; 92:641.</a></li></ol></div><div id="topicVersionRevision">Topic 2906 Version 13.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11977176" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Clinical and genetic variability of glycogen storage disease type IIIa: seven novel AGL gene mutations in the Mediterranean area.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1505983" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Assignment of the human glycogen debrancher gene to chromosome 1p21.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1374391" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Molecular cloning and nucleotide sequence of cDNA encoding human muscle glycogen debranching enzyme.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8954797" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Human glycogen debranching enzyme gene (AGL): complete structural organization and characterization of the 5' flanking region.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26984562" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Spectrum of AGL mutations in Chinese patients with glycogen storage disease type III: identification of 31 novel mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25602008" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A founder AGL mutation causing glycogen storage disease type IIIa in Inuit identified through whole-exome sequencing: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11378828" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Molecular genetic basis and prevalence of glycogen storage disease type IIIA in the Faroe Islands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9412782" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A single-base deletion in the 3'-coding region of glycogen-debranching enzyme is prevalent in glycogen storage disease type IIIA in a population of North African Jewish patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19834502" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Molecular features of 23 patients with glycogen storage disease type III in Turkey: a novel mutation p.R1147G associated with isolated glucosidase deficiency, along with 9 AGL mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17407002" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Serum lipid and lipoprotein profile of patients with glycogen storage disease types I, III and IX.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24716397" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Glycogen storage disease type III in Israel: presentation and long-term outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26924264" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Reduced bone mineral density in glycogen storage disease type III: evidence for a possible connection between metabolic imbalance and bone homeostasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9138172" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Hepatocellular adenomas in glycogen storage disease type I and III: a series of 43 patients and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26697579" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Hepatocellular Adenomas and Carcinoma in Asymptomatic, Non-Cirrhotic Type III Glycogen Storage Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8253364" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A man with type III glycogenosis associated with cirrhosis and portal hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27106217" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Glycogen storage disease type III: diagnosis, genotype, management, clinical course and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/288318" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Debrancher deficiency: neuromuscular disorder in 5 adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4519535" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Myopathy associated with type 3 glycogenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3457519" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Neuromuscular involvement in glycogen storage disease type III.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5285455" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Type 3 glycogenosis. An adult with diffuse weakness and muscle wasting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3457549" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Accumulation of glycogen in sural nerve axons in adult-onset type III glycogenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35433175" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Glycogen storage disease type IIIa in pregnant women: A guide to management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25388549" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Cognitive profile of patients with glycogen storage disease type III: a clinical description of seven cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23430941" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Cardiac Pathology in Glycogen Storage Disease Type III.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9187419" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Obstructive hypertrophic cardiomyopathy in type III glycogen-storage disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9076400" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Specific heart muscle disease associated with glycogen storage disease type III: clinical similarity to the dilated phase of hypertrophic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17895567" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : A Japanese patient with cardiomyopathy caused by a novel mutation R285X in the AGL gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20071996" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The electrodiagnostic characteristics of Glycogen Storage Disease Type III.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20071996" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The electrodiagnostic characteristics of Glycogen Storage Disease Type III.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8245377" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Nutrition therapy for hepatic glycogen storage diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19322675" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Reversal of glycogen storage disease type IIIa-related cardiomyopathy with modification of diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25308556" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Improvement of Cardiomyopathy After High-Fat Diet in Two Siblings with Glycogen Storage Disease Type III.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17514432" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : A novel starch for the treatment of glycogen storage diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26303612" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Safety and Efficacy of Chronic Extended Release Cornstarch Therapy for Glycogen Storage Disease Type I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31844626" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Use of waxy maize heat modified starch in the treatment of children between 2 and 5 years with glycogen storage disease type I: A retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23430911" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Heart Failure Due to Severe Hypertrophic Cardiomyopathy Reversed by Low Calorie, High Protein Dietary Adjustments in a Glycogen Storage Disease Type IIIa Patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31309177" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Modified Atkins ketogenic diet improves heart and skeletal muscle function in glycogen storage disease type III.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32064649" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Dietary lipids in glycogen storage disease type III: A systematic literature study, case studies, and future recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17539004" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Long-term results of living donor liver transplantation for glycogen storage disorders in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35313948" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Liver transplantation in glycogen storage disease: a single-center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29321839" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Liver Transplantation in a Myopathic Patient with Glycogen Storage Disease Type IIIa and Decompensated Cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23318145" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Alglucosidase alfa enzyme replacement therapy as a therapeutic approach for glycogen storage disease type III.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24509886" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Correction of glycogen storage disease type III with rapamycin in a canine model.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
